Overview

Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
The primary objectives are a) to establish the maximum tolerated dose of gemtuzumab ozogamicin in combination with cytarabine and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine.
Phase:
Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Cytarabine
Gemtuzumab